Capricor Therapeutics, Inc.
CAPR
$6.97
$0.081.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.27M | 23.23M | 27.15M | 27.10M | 25.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.27M | 23.23M | 27.15M | 27.10M | 25.18M |
| Cost of Revenue | 49.97M | 45.35M | 43.58M | 39.89M | 36.45M |
| Gross Profit | -27.70M | -22.13M | -16.42M | -12.79M | -11.27M |
| SG&A Expenses | 14.87M | 14.02M | 13.58M | 13.37M | 12.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.84M | 59.38M | 57.16M | 53.26M | 49.26M |
| Operating Income | -42.56M | -36.15M | -30.00M | -26.16M | -24.08M |
| Income Before Tax | -40.47M | -34.11M | -27.95M | -24.31M | -22.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.47 | -34.11 | -27.95 | -24.31 | -22.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.47M | -34.11M | -27.95M | -24.31M | -22.29M |
| EBIT | -42.56M | -36.15M | -30.00M | -26.16M | -24.08M |
| EBITDA | -41.14M | -34.79M | -28.73M | -24.99M | -23.01M |
| EPS Basic | -1.20 | -1.06 | -0.93 | -0.88 | -0.87 |
| Normalized Basic EPS | -0.75 | -0.66 | -0.58 | -0.55 | -0.54 |
| EPS Diluted | -1.20 | -1.06 | -0.93 | -0.88 | -0.87 |
| Normalized Diluted EPS | -0.75 | -0.66 | -0.58 | -0.55 | -0.54 |
| Average Basic Shares Outstanding | 140.80M | 126.95M | 119.68M | 113.17M | 107.06M |
| Average Diluted Shares Outstanding | 140.80M | 126.95M | 119.68M | 113.17M | 107.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |